SynCore Biotechnology Co (ROCO:4192) LT-Debt-to-Total-Asset : 0.01 (As of Sep. 2024)

View and export this data going back to 2014. Start your Free Trial

What is SynCore Biotechnology Co LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. SynCore Biotechnology Co's long-term debt to total assests ratio for the quarter that ended in Sep. 2024 was 0.01.

SynCore Biotechnology Co's long-term debt to total assets ratio increased from Sep. 2023 (0.00) to Sep. 2024 (0.01). It may suggest that SynCore Biotechnology Co is progressively becoming more dependent on debt to grow their business.

SynCore Biotechnology Co LT-Debt-to-Total-Asset Historical Data

The historical data trend for SynCore Biotechnology Co's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SynCore Biotechnology Co LT-Debt-to-Total-Asset Chart

SynCore Biotechnology Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.02

0.01

SynCore Biotechnology Co Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															-	-	0.01	0.01	0.01

SynCore Biotechnology Co LT-Debt-to-Total-Asset Calculation

SynCore Biotechnology Co's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	0	/	378.362
	=	0.00

SynCore Biotechnology Co's Long-Term Debt to Total Asset Ratio for the quarter that ended in Sep. 2024 is calculated as

LT Debt to Total Assets (Q: Sep. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Sep. 2024 )	/	Total Assets (Q: Sep. 2024 )
	=	2.467	/	331.788
	=	0.01

SynCore Biotechnology Co (ROCO:4192) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

SynCore Biotechnology Co LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of SynCore Biotechnology Co's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

SynCore Biotechnology Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SynCore Biotechnology Co Ltd (ROCO:4192) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

No.84 Zhongshan Road, Zhongshan Village, Dongshan Township, Yilan, TWN, 269

Website

https://www.syncorebio.com

SynCore Biotechnology Co Ltd is a Biotechnology company. Its pipeline products concentrate on the ophthalmology, oncology, and dermatology fields. The pipeline products of the company include SB01 and 02, SB03, SB04, and SB05. It is engaged in drug development and sale, food advisory, medicine inspection, biotechnology service, and intellectual property. It operates in a single industry, the new drug development. The company generates the majority of its revenue from Healthy food sales.

SynCore Biotechnology Co Headlines

No Headlines